X-Square Capital’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

X-Square Capital’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-31,720	Closed	-$48K	–	164
2023 Q1	$48K	Sell	31,720 -199	-0.6%	-$268	0.03%	144
2022 Q4	$32K	Hold	31,919	–	–	0.02%	147
2022 Q3	$57K	Hold	31,919	–	–	0.04%	140
2022 Q2	$93K	Sell	31,919 -84	-0.3%	-$207	0.06%	142
2022 Q1	$88K	Hold	32,003	–	–	0.05%	144
2021 Q4	$149K	Hold	32,003	–	–	0.07%	139
2021 Q3	$272K	Sell	32,003 -3,755	-11%	-$53.1K	0.14%	126
2021 Q2	$587K	Hold	35,758	–	–	0.28%	85
2021 Q1	$790K	Buy	35,758 +3,416	+11%	+$93.1K	0.37%	74
2020 Q4	$1M	Buy	+32,342	New	+$818K	0.54%	54

X-Square Capital's TCRR Position: Q2 2023 in Review

X-Square Capital sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 31,720 shares — an estimated $48K sold.

X-Square Capital first reported a position in TCRR in Q4 2020 and held it in 10 quarters. The position peaked at $1M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

X-Square Capital reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
X-Square Capital sold 31,720 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $48K.
X-Square Capital first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 10 quarters.
X-Square Capital's TCR2 Therapeutics Inc. Common Stock position peaked at $1M in Q4 2020.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on X-Square Capital's 13F filing for Q2 2023, filed 14 Aug 2023.